Mok Park - DongKook Pharmaceutical Managing Director
| 086450 Stock | KRW 18,320 200.00 0.17% |
Managing Director
Park Mok Sun is Managing Director of DongKook Pharmaceutical Co. Ltd. Previously Park worked for Hanall Pharmaceutical Co. Ltd. Park received a Bachelor degree in Pharmacy from ChungNam National University Korea in February 1984. since 2007.
| Age | 57 |
| Tenure | 17 years |
| Phone | (82) 2 566 8542 |
| Web | www.dkpharm.co.kr |
DongKook Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0608 % which means that it generated a profit of $0.0608 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 12.717 %, meaning that it generated $12.717 on every $100 dollars invested by stockholders. DongKook Pharmaceutical's management efficiency ratios could be used to measure how well DongKook Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.DongKook Pharmaceutical Co has accumulated 13.69 B in total debt with debt to equity ratio (D/E) of 0.15, which may suggest the company is not taking enough advantage from borrowing. DongKook Pharmaceutical has a current ratio of 2.56, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DongKook Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, DongKook Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DongKook Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DongKook to invest in growth at high rates of return. When we think about DongKook Pharmaceutical's use of debt, we should always consider it together with cash and equity.
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea. DongKook Pharm is traded on Korean Securities Dealers Automated Quotations in South Korea. DongKook Pharmaceutical Co (086450) is traded on KOSDAQ in Korea and employs 1,056 people. Management Performance
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 |
DongKook Pharmaceutical Leadership Team
Elected by the shareholders, the DongKook Pharmaceutical's board of directors comprises two types of representatives: DongKook Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DongKook. The board's role is to monitor DongKook Pharmaceutical's management team and ensure that shareholders' interests are well served. DongKook Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DongKook Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gyeong Cha, Managing Director | ||
| GyuJin Lee, Managing Management | ||
| Bong Cho, Assistant Managing Director | ||
| HongKi Kim, Director Fin | ||
| Heung Oh, Chief Executive Officer, Director | ||
| Gi Kwon, Vice Chairman of the Board | ||
| Jae Park, Assistant Managing Director | ||
| HeeSoon Park, Managing Marketing | ||
| Mok Park, Managing Director | ||
| Se Jeon, Assistant Managing Director | ||
| Gi Jung, Managing Director | ||
| YoungWook Lee, Pres CEO | ||
| BongHo Cho, Managing Sales | ||
| Byeong Yoo, Managing Director | ||
| Seung Pyo, Assistant Managing Director | ||
| Gyu Jung, Internal Auditor | ||
| Hui Kim, Managing Director | ||
| Tae Kim, Assistant Managing Director | ||
| HeungJu Oh, VP CEO | ||
| SoonKang Hong, Managing PR | ||
| SeIl Jeon, Managing Sales | ||
| JoonHo Song, Managing Planning | ||
| JeWon Park, Managing Sales | ||
| Byeong Yeo, Director |
DongKook Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DongKook Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 1.08 T | |||
| Shares Outstanding | 8.79 M | |||
| Shares Owned By Insiders | 46.60 % | |||
| Shares Owned By Institutions | 17.00 % | |||
| Price To Earning | 19.52 X | |||
| Price To Sales | 0.24 X |
Other Information on Investing in DongKook Stock
DongKook Pharmaceutical financial ratios help investors to determine whether DongKook Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DongKook with respect to the benefits of owning DongKook Pharmaceutical security.